Weight loss typically continues, with clinical trials showing that semaglutide 2.4 mg (Wegovy) produces average weight loss of approximately 15% by week 68, while tirzepatide (Zepbound) has demonstrated weight loss of approximately 15-21% across different doses by week 72
GLP-3 (Retatrutide) from Peptra Labs is supplied strictly as laboratory research material and must not be used as a human or veterinary product
By combining medical care with realistic lifestyle strategies, we help patients move forward with confidence, clarity, and long-term success
We accept ACH and credit card payments, billed only when your order ships
However, rigorous clinical trial data specifically for tirzepatide remain limited Direct Effects
That simplicity prevents calculation errors during the weeks of titration ahead